David L. Guy

P.O. Box ******, Rancho Santa Fe, CA 92067

Phone (C): 858-***-**** (H): 858-***-****

abnita@r.postjobfree.com

SUMMARY OF QUALIFICATIONS

Successful launch and/or commercialization of many oncology brands (Taxotere®,

Rituxan®, Fludara®, Campath®, Zevalin® and Herceptin®)

Built and led sales teams at RPR and Sanofi.

Leadership experience as CEO of a start-up company, CCO at Favrille, Head of an

Oncology Global Business Unit at Schering AG/ Berlex (now Bayer) and Head of

Oncology Marketing at Genentech.

Creation and management of multiple commercialization partnerships and licensing

deals.

Expert knowledge of leading oncology indications & markets: Lymphoma, Leukemia,

Breast Cancer, Lung Cancer, Colon Cancer, Prostate Cancer and Supportive Care.

Expert in the reimbursement and distribution of oncology & specialty products.

Additional functional areas successfully led include: Medical Affairs, Medical

Communications, Forecasting, Distribution and Reimbursement.

EMPLOYMENT HISTORY

Intrepid Therapeutics Inc., 2008 - Present

President and CEO

In June, 2008 following the failure of Favrille’s clinical program and subsequent

workforce reduction, I was invited by a member of the Board of Directors (Cam Garner)

to work with himself and two other prominent local biotech entrepreneurs (David Hale,

Scott Glenn) to found an oncology company. The goal of the company is to in-license

early and mid-stage oncology therapeutics and supportive care products advance their

development and eventually commercialize them. Several products have been

identified and terms successfully negotiated to acquire them. W e are currently seeking

financing to secure the products and establish the company.

Favrille, 2005 – 2008

Chief Commercial Officer

Responsible for all Commercial activities and budget for the company. Focused on

the launch of Specifid™ and licensing activities (in & out).

Key activities: branding, key messages, medical communications, CME, KOL

development, congress presence, investor relations, out-licensing search,

market research, financial modeling, and investigator initiated studies,

development and implementation of the Specifid commercialization plan.

Functional responsibilities included: Medical Affairs, Publications, Product

Management, Marketing, Sales, Managed Care, Distribution, Project

Management and Business Development

David L. Guy

P.O. Box 675347, Rancho Santa Fe, CA 92067

Phone (C): 858-***-**** (H): 858-***-****

abnita@r.postjobfree.com

Schering AG/Berlex (now Bayer), 2002 – 2005

Global Business Unit Head, Oncology 2004-2005

Led strategic initiative that identified Oncology as growth driver for the company.

Recommendations resulted in a global re-organization and interim leadership

position responsible for:

All commercial and development activities

P&L responsibility

150 Mio Euro budget, 200+ staff, 250+ Mio Euro sales

Implemented re-organization to new GBU structure

Vice President, Global Strategic Marketing and Business Development, Oncology

2002-2004

Responsible for all global strategic marketing activities

Key activities: branding, commercial strategy, forecasting, PR, medical affairs

and commercial input into development and regulatory strategies

Staff of 15 and a budget in excess of 20 million euros

Product Portfolio included: Fludara®, Campath®, Zevalin®, Leukine®,

Bonefos®, PTK787, MS-209, MS-275, Epothilone

Supported the Launch of Zevalin® in the EU and commercialization of

Campath® in the US

Provided strategic and commercial leadership for oncology in-licensing/out-

licensing projects (i.e. PTK787, Leukine) ®. Development and management of key

partnerships (Novartis (PTK-787), Genzyme (Campath®), Biogen-Idec (Zevalin®))

Genentech, 2000-2002

Director, Oncology Marketing

Responsible for all the marketing activities for Rituxan and Herceptin :

Doubled Rituxan dollar sales (from $400 to $800 million)

Re-launched and reversed a slowing growth trend for Herceptin

Managed a 15-person department and promotional spend of $40 million

Provided commercial strategic leadership for oncology products in development,

discovery and acquisition

Sanofi- Aventis 1994-2000

US Business Unit Head, Oncology (Sanofi US) 1999-2000

Responsible for the management, sales and profitability of an integrated oncology

business unit

Managed a 23-person staff of sales, marketing, medical and market research

personnel

Member of the Operating Committee

Reported directly to the COO

Key member of the Sanofi/Eli Lilly joint venture Board of Management for the

chemotherapeutic agent Eloxatin® (oxaliplatin)

Lead pre-approval launch activities for Eloxatin® (oxaliplatin)

David L. Guy

P.O. Box 675347, Rancho Santa Fe, CA 92067

Phone (C): 858-***-**** (H): 858-***-****

abnita@r.postjobfree.com

Area Business Manager (RPR US), Oncology 1997-1999

Responsible for the sales of Taxotere and Gliadel for the Texas-New Mexico

area and management of a 10 person sales team

Responsibilities included: recruiting, promotional and expense budget management,

thought leader development, team building

Accomplishments included having the #1 performing area

International Senior Product Manager (RPR US), Taxotere® 1995-1997

Responsible for global communication strategy/ implementation and affiliates

relations (pricing, resource allocation, strategy, support) for the Americas and

Asia/Pacific

Supported the launch of Taxotere® in the US, Australia and Japan.

Provided commercial need input to R&D for indication development

Senior Product Manager, Oncology (RPR Canada), 1994-1995

Responsible for the launch of Taxotere and management of the Oncology portfolio

Launched M-Eslon®, a slow release morphine product

Additional responsibilities included managing the groups P&L, providing R&D

strategic direction

Berlex Canada Inc., 1992-1994

Product Manager, Oncology

Responsible for the launch of the anti-leukemia drug, Fludara and management of

the #1 selling prostate cancer drug, Androcur

Burroughs Wellcome Inc. (Canada), 1988-1992

Associate Product Manager, Virology/Oncology, 1991-92

Achievements included the launch of W ellferon (interferon alpha-n1) and the

maintenance of sales for Zovirax I.V. (acyclovir) in a declining market

Sales Representative, 1988-91

Responsible for sales of Retrovir (zidovudine, AZT), Zovirax I.V. (acyclovir) and

oncology products in the Toronto teaching hospitals

Exceeded budget every year

McMaster University, Hamilton 1986-1988

Research Assistant (Immunology, Oncology)

Involved in AIDS research exploring mechanisms of cell mediated immunity and

possible vaccines

Oncology research led to co-authorship of an article published in Cancer Research

AFFILIATIONS:

2007-2008 Cancer Vaccine Consortium, Executive Council

2002-2007 ASCO Member

EDUCATION: McMaster University, Hamilton, Ontario

1981-1985 Granted Bachelor of Science in 1985. Major in biology with a

specialization in molecular genetics

David L. Guy

P.O. Box 675347, Rancho Santa Fe, CA 92067

Phone (C): 858-***-**** (H): 858-***-****

abnita@r.postjobfree.com

EXTRACURRICULAR INTERESTS:

Hobbies include: spending time with my family (daughter age 6, son

age 4), sailing, reading, skiing, photography, travel and wine collecting

Contact this candidate